Skip to main content

Table 4 Unadjusted odds of completing M6 in 1011 participants by baseline patient characteristics and other variables

From: The impact of non-medical cannabis legalization and other exposures on retention in longitudinal cannabis research: a survival analysis of a prospective study of Canadian medical cannabis patients

Patient characteristics Univariate analysis
ORa 95% CIb P
Gender
  Female  
  Male 0.93 0.72, 1.20 0.587
Education
  College or lower  
  High school or lower 0.86 0.67, 1.11 0.252
Marital status
  Married/living as married  
  Single/divorced/widowed/separated 0.83 0.64, 1.06 0.140
Age
  < 55  
  ≥ 55 1.21 0.94, 1.57 0.135
Used cannabis for any reason 5 or more times in the last 12 months
  No  
  Yes 0.93 0.72, 1.20 0.579
Primary illness or medical condition you currently treat with medical cannabis
  Pain  
  Mental health issues 0.79 0.52, 1.20 0.275
  Insomnia 0.98 0.54, 1.77 0.942
  Other 0.94 0.56, 1.57 0.805
Use of opioid
  N  
  Y 0.69 0.52, 0.92 0.011
Use of non-opioid pain medications
  N  
  Y 1.13 0.83, 1.53 0.439
Use of benzodiazepine
  N  
  Y 1.32 0.81, 2.18 0.269
Use of antidepressant
  N  
  Y 1.52 1.09, 2.13 0.014
Use of anti-seizure
  N  
  Y 1.68 1.19, 2.36 0.003
Opioid—dose per day (DDD)
  > 0, < 0.57  
  ≥ 0.57 0.67 0.38, 1.17 0.157
Non-opioid pain medications—dose per day (DDD)
  > 0, < 0.43  
  ≥ 0.43 0.72 0.39, 1.33 0.289
Benzodiazepine—dose per day (DDD)
  > 0, < 0.38  
   ≥ 0.38 1.54 0.54, 4.42 0.423
Antidepressant—dose per day (DDD)
  > 0, < 1  
  ≥ 1 1.50 0.68, 3.31 0.316
Anti-seizure—dose per day (DDD)
  > 0, < 0.5  
  ≥ 0.5 0.82 0.39, 1.72 0.60
WHOQOL—physical health (baseline)
  < 36  
  ≥ 36 1 0.78, 1.28 0.981
WHOQOL—psychological (baseline)
  < 54  
  ≥ 54 1.33 1.03, 1.71 0.028
WHOQOL—social relationships (baseline)
  < 58  
  ≥ 58 1.23 0.95, 1.60 0.114
WHOQOL—environment (baseline)
  < 66  
  ≥ 66 1.15 0.89, 1.47 0.289
Cannabis use per week (g)
  < 5  
  ≥ 5 1.06 0.83, 1.36 0.645
Frequency of cannabis use per week    
  < 14  
  ≥ 14 1.11 0.87, 1.44 0.401
Currently using Tilray extract products
  N  
  Y 0.91 0.70, 1.18 0.479
Preferred type of cannabis
  CBD  
  THC 1.29 0.94, 1.78 0.113
  No preference 1.56 1.16, 2.10 0.004
Primary method of use
  Inhaled  
  Orally ingested 0.72 0.56, 0.93 0.012
Enrollment period
  Enrolled prior to 17 April 2018 (M6 would be pre-legalization)  
  Enrolled between 17 April and 15 July 2018 (M6 would be post legalization) 0.32 0.22, 0.46  < 0.001
  1. aOR  Odds ratio, bCI Confidence interval